Alzheimer’s disease (AD) affects over 6 million Americans—and despite decades of research, there’s still no cure. But a new approach is challenging the way we think about the disease.
Lighthouse Pharmaceuticals just secured a $49.2 million grant from the National Institute on Aging (NIA) to run a Phase 2 clinical trial of its experimental drug LHP588. Unlike traditional treatments, this therapy zeroes in on a surprising culprit: a bacterial infection.
Why Targeting Infection in Alzheimer’s Could Be Game-Changing?
For years, researchers have suspected that Porphyromonas gingivalis (P. gingivalis), a bacterium best known for causing gum disease—might play a role in Alzheimer’s.
Here’s the connection:
- P. gingivalis produces gingipains – toxic enzymes that trigger inflammation and damage brain cells.
- These enzymes can accelerate amyloid-beta accumulation and tau tangles, the classic hallmarks of Alzheimer’s.
- Chronic infection = chronic inflammation = faster cognitive decline.
If true, stopping the bacteria’s toxins could slow—or even change—the course of the disease.
Meet LHP588: The Gingipain Blocker
LHP588 is a brain-penetrant oral drug designed to shut down one of P. gingivalis’s most dangerous weapons: lysine-gingipain (Kgp).
- How it works: Blocks Kgp activity → reduces bacterial toxicity → lowers inflammation in the brain.
- Why it matters: A previous trial of a similar inhibitor showed slower cognitive decline in AD patients who tested positive for P. gingivalis.
This is precision medicine in action—treating the patients whose biology matches the drug’s mechanism.
Inside the SPRING Trial
The new trial, called SPRING (Stopping PRogression of P. gINGivalis-positive Alzheimer’s with gingipain inhibition), will test LHP588 in:
- 300 patients with mild-to-moderate Alzheimer’s
- Confirmed P. gingivalis infection via a saliva test
- Randomized, double-blind, placebo-controlled design
- High- and low-dose arms compared against placebo
In short: it’s a rigorous test of whether infection-driven Alzheimer’s can be slowed with a targeted therapy.
Why This Matters?
This trial could mark a turning point in Alzheimer’s research:
- Instead of treating symptoms, it targets a possible root cause.
- It validates the role of infection and inflammation in neurodegeneration.
- It opens the door to precision therapies—treatments matched to subgroups of patients.
Casey Lynch, CEO of Lighthouse Pharma, put it simply:
“We’re proud to lead this pioneering trial aimed at modifying the disease process by targeting a known microbial driver of neuroinflammation and neurodegeneration.”
The Big Picture
Alzheimer’s has resisted every “one-size-fits-all” treatment so far. But what if the key is not one disease, but many pathways leading to cognitive decline?
By focusing on the P. gingivalis-positive subgroup, Lighthouse is testing that idea. If successful, it could:
- Redefine Alzheimer’s as a precision-medicine disease.
- Give patients and families a new path forward.
- Change how we fight other neurodegenerative conditions linked to chronic infections.
The stakes are high—but so is the potential impact.
